

Haiyong Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2710024/publications.pdf>

Version: 2024-02-01

48
papers

588
citations

759190

12
h-index

713444

21
g-index

52
all docs

52
docs citations

52
times ranked

854
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study. <i>Oncotarget</i> , 2017, 8, 26368-26379.	1.8	64
2	Screening differential circular RNA expression profiles reveal that hsa_circ_0128298 is a biomarker in the diagnosis and prognosis of hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 1275-1283.	1.9	51
3	Circular RNA Hsa_Circ_0091579 Serves as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 290-300.	1.6	38
4	Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 20510-20515.	1.8	37
5	The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study. <i>Future Oncology</i> , 2018, 14, 1397-1407.	2.4	36
6	TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment. <i>Cancer Medicine</i> , 2020, 9, 7151-7160.	2.8	33
7	CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. <i>Cancer Cell International</i> , 2020, 20, 583.	4.1	31
8	Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2019, 17, 2091-2098.	1.8	25
9	Total lymphocyte count, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio as prognostic factors in advanced non–small cell lung cancer with chemoradiotherapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 6677-6683.	1.9	25
10	Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 81906-81917.	1.8	20
11	Preoperative radiation may improve the outcomes of resectable IIIA/N2 non-small cell lung cancer patients: A propensity score matching–based analysis from surveillance, epidemiology, and end results database. <i>Cancer Medicine</i> , 2018, 7, 4354-4360.	2.8	18
12	Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III. <i>Oncotarget</i> , 2017, 8, 34923-34934.	1.8	14
13	Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion. <i>Oncotarget</i> , 2017, 8, 35262-35271.	1.8	13
14	Poor survival of non-small-cell lung cancer patients with main bronchus tumor: a large population-based study. <i>Future Oncology</i> , 2019, 15, 2819-2827.	2.4	12
15	Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis. <i>Future Oncology</i> , 2018, 14, 2371-2381.	2.4	11
16	A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-9.	1.9	11
17	Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer. <i>Future Oncology</i> , 2017, 13, 1149-1158.	2.4	10
18	Including positive lymph node count in the AJCC N staging may be a better predictor of the prognosis of NSCLC patients, especially stage III patients: a large population-based study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1359-1366.	2.2	10

#	ARTICLE	IF	CITATIONS
19	PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. <i>Lung Cancer</i> , 2021, 151, 76-83.	2.0	10
20	KEAP1-NFE2L2 Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis. <i>Journal of Thoracic Oncology</i> , 2020, 15, e85-e86.	1.1	9
21	Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100006.	1.1	8
22	Better survival in PMRT of female breast cancer patients with >5 negative lymph nodes. <i>Medicine (United States)</i> , 2017, 96, e5998.	1.0	7
23	Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more. <i>Future Oncology</i> , 2018, 14, 2131-2138.	2.4	7
24	A Novel Nomogram including AJCC Stages Could Better Predict Survival for NSCLC Patients Who Underwent Surgery: A Large Population-Based Study. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	1.3	7
25	Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study. <i>Oncotarget</i> , 2016, 7, 75492-75502.	1.8	7
26	Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different driver genes: case report and literature review. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4639-4644.	2.0	6
27	Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?. <i>Frontiers in Immunology</i> , 2018, 9, 2916.	4.8	6
28	Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	6
29	PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study. <i>Cancer Management and Research</i> , 2018, Volume 10, 3561-3567.	1.9	5
30	Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 3001-3006.	1.9	5
31	Postmastectomy radiation therapy for breast cancer patients with one to three positive lymph nodes: a propensity score matching analysis. <i>Future Oncology</i> , 2017, 13, 1395-1404.	2.4	4
32	Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8421-8426.	2.0	4
33	Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report. <i>Cancer Biology and Therapy</i> , 2018, 19, 1073-1077.	3.4	4
34	Radiotherapy may improve survival of ES&SCLC with distant metastasis only for patients with one metastatic site: A population&based study. <i>Oncology Letters</i> , 2020, 19, 139-146.	1.8	4
35	Young male breast cancer, a small crowd, the survival, and prognosis?. <i>Medicine (United States)</i> , 2018, 97, e12686.	1.0	3
36	Application of prophylactic cranial irradiation in limited-stage small-cell lung cancer: which patients could benefit?. <i>Future Oncology</i> , 2019, 15, 23-31.	2.4	3

#	ARTICLE	IF	CITATIONS
37	The appropriate number of ELNs for lymph node negative breast cancer patients underwent MRM: a population-based study. <i>Oncotarget</i> , 2017, 8, 65668-65676.	1.8	3
38	High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 2675-2682.	0.5	3
39	Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8+ T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4209-4220.	1.8	3
40	Characteristics and survival difference of clinical tumor size 0 extensive-stage small cell lung cancer with different metastasis pattern. <i>Journal of Thoracic Disease</i> , 2018, 10, 5414-5420.	1.4	2
41	Surgical intervention may be a therapeutic option for NSCLC patients with AJCC stage IV: a large population-based study. <i>Cancer Management and Research</i> , 2018, Volume 10, 3219-3226.	1.9	2
42	A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab. <i>Frontiers in Immunology</i> , 2021, 12, 606027.	4.8	2
43	A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab. <i>Cancer Medicine</i> , 2021, 10, 6218-6226.	2.8	2
44	Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6899-6906.	1.8	2
45	How many ELNs are optimal for breast cancer patients with more than three PLNs who underwent MRM? A large population-based study. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1005-1011.	2.0	1
46	Incorporating the Number of PLN into the AJCC Stage Could Better Predict the Survival for Patients with NSCLC: A Large Population-Based Study. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	1
47	Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed. <i>Oncotarget</i> , 2017, 8, 74910-74916.	1.8	1
48	A prognostic score model to determine which breast cancer patients with 1-3 positive lymph nodes after modified radical mastectomy should receive radiotherapy. <i>Oncotarget</i> , 2018, 9, 385-393.	1.8	0